]>
IRCT20190109042312N1 IRCT 2019-02-19 Zahedan University of Medical Sciences Effect of Levofloxacin and Azithromycin in bronchiectasis patients treatment The preventive effects of short-course treatment with Levofloxacin in comparison with Azithromycin in bronchiectasis patients 2019-02-19 anticipated 82 Complete https://irct.ir/trial/36768 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients randomly divided into two groups receiving Azithromycin or Levofloxacin on the basis of random numbers. Medications will be marked with codes A and B and will be in the same shape, Blinding description: Medications will be identified with codes A and B and will be in the same shape, and therefore the patient and the assessing person (physician) will not know how patients allocated. 3 Bronchiectasis. Intervention 1: Intervention group: Levofloxacin - In this group, patients will receive Levofloxacin for 5 days with the dose of 500mg in a month and will be followed for one year, during that time the number of admissions and the number of exacerbations will be examined and compared. Intervention 2: Intervention group: Azithromycin - In this group, patients will receive Azithromycin at a dose of 250 mg per day throughout the study period and will be followed for one year, during that time the number of admissions and the number of exacerbations will be examined and compared. Yes - There is a plan to make this available What will be shared: Only part of the data, such as information on the main outcome, can be shared. When: Start the access period 6 months after printing the results To whom: Data will only be available to academic researchers Conditions: It is only allowed to use the data to give ideas for future research Where to obtain: Access to the documentation will be possible through the University's Research deputy How to obtain: Access to the documentation will be possible by following the relevant routine Comments:
public Farzane Peykfalak
Zahedan University of Medical Scienses, Dr Hesabi sq., Zahedan, Iran
Zahedan Iran (Islamic Republic of) 9816743463 +98 54 3329 5789 farzane_p471@zaums.ac.ir Zahedan University of Medical Sciences scientific Farzane Peykfalak
Zahedan University of Medical Scienses, Dr Hesabi sq., Zahedan, Iran
Zahedan Iran (Islamic Republic of) 9816743463 +98 54 3329 5789 farzane_p471@zaums.ac.ir Zahedan University of Medical Sciences Iran (Islamic Republic of) Having a definitive diagnosis of bronchiectasis Satisfaction to participate in the study no limit no limit Both Having cystic fibrosis, allergies, asthma, tuberculosis J47 Bronchiectasis Treatment - Drugs Treatment - Drugs Intervention group: Levofloxacin - In this group, patients will receive Levofloxacin for 5 days with the dose of 500mg in a month and will be followed for one year, during that time the number of admissions and the number of exacerbations will be examined and compared. Intervention group: Azithromycin - In this group, patients will receive Azithromycin at a dose of 250 mg per day throughout the study period and will be followed for one year, during that time the number of admissions and the number of exacerbations will be examined and compared. Exacerbation. Timepoint: During and after the end of the data collection. Method of measurement: By the form of information. Number of admissions. Timepoint: During and after the end of the data collection. Method of measurement: By the form of information. Zahedan University of Medical Sciences Approved 2019-02-03 Ethics committee of Zahedan University of Medical Sciences Zahedan University of Medical Scienses, Dr Hesabi sq., Zahedan, Iran Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)